MDRNA, Inc.
3830 Monte Villa Parkway
Bothell,
WA 98021
United States - Map
Phone: 425-908-3600
Fax: 425-908-3650
Web Site: http://www.mdrnainc.com
| MDRNA, Inc. operates as a biotechnology company focused on the development and commercialization of therapeutic products based on RNA interference (RNAi). The company seeks to improve human health by combining RNAi-based compounds and proprietary peptide- and liposomal-based drug delivery technologies to provide therapeutic options. MDRNA's multi-disciplinary portfolio of capabilities includes molecular biology, cellular biology, formulation expertise, peptide and alkylated amino acid chemistry, pharmacology, toxicology, and bioinformatics. The company is applying this expertise to a single, integrated drug discovery platform that would be the engine for its clinical pipeline and a versatile platform for establishing therapeutic partnerships. MDRNA is also building on new technologies, such as UsiRNAs that incorporate the non-nucleotide moiety Unlocked Nucleobase Analog (UNA) within the siRNA molecule, that might lead to safer and more effective RNAi-based therapeutics. The company combines expertise in siRNA science with proven delivery platforms and a growing IP portfolio, positioning MDRNA as an RNAi therapeutics company and a value-added collaborator for its research partners. It was formerly known as Nastech Pharmaceutical Company Inc. and changed its name to MDRNA, Inc. The company was founded in 1983 and is headquartered in Bothell, Washington. |
|
| Key Statistics |
| |
| | Pay | Exercised | Mr. J. Michael French , 49
Chief Exec. Officer, Pres |
$
176.00K |
$
0 | Mr. Bruce R. York , 54
Chief Accounting Officer and VP of Fin. |
$
224.00K |
$
0 | Mr. Peter S. Garcia , 48
Chief Financial Officer and Sec. |
N/A
| N/A | Dr. Barry Polisky Ph.D., 62
Chief Scientific Officer |
N/A
| N/A | Mr. Matthew D. Haines , 55
Sr. Director of Investor Relations and Corp. Communications |
N/A
| N/A |
|
|
|
Dollar amounts are as of
31-Dec-08
and compensation values are for the last fiscal
year ending on that date. "Pay" is salary, bonuses, etc. "Exercised" is the value of
options exercised during the fiscal year.
| |
|
1.23% Nasdaq 0.00%
Profile
